Related Experiment Video
Updated: Jan 27, 2026

Production of Human CRISPR-Engineered CAR-T Cells
Published on: March 15, 2021
Multi Targeted CAR-T Cell Therapies for B-Cell Malignancies
Nirav N Shah1, Theresa Maatman2, Parameswaran Hari1
1Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI, United States.
Abstract:
Chimeric antigen receptor (CAR) modified T cell therapy has revolutionized the treatment of relapsed and refractory hematological malignancies. Through targeting of the CD19 antigen on B cells durable remissions have been achieved in patients with B cell non-Hodgkin lymphoma and acute lymphoblastic lymphoma. Despite impressive responses, multiple escape mechanisms to evade CAR-T cell therapy have been identified, among which the most common is loss of the target antigen. In this review we will highlight outcomes to date with CD19 CAR-T cell therapy, describe the current limitations of single targeted CAR-T therapies, review identified tumor escape mechanisms, and lastly discuss novel strategies to overcome resistance via multi-targeted CAR-T cells.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Target Cell Response to Hormones
Notably, the cellular response can be regulated by altering the number of receptors expressed in the cell. For example, prolonged exposure to elevated hormone levels results in a gradual decline or down-regulation in the number of receptors for that specific hormone on the cell surface. Conversely, in response to low hormone levels, cells may use up-regulation, producing an...
Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
Gene Therapy
Group Therapy
Multi-input and Multi-variable systems
In the absence of...

